ZA200403088B - Use of (11beta, 17beta)-11-(1,3-benzodioxol-5-yl)-17-hydroxy-17-(1-propynyl)-estra-4,9-dien-3-one in the treatment of major depressive disorder. - Google Patents
Use of (11beta, 17beta)-11-(1,3-benzodioxol-5-yl)-17-hydroxy-17-(1-propynyl)-estra-4,9-dien-3-one in the treatment of major depressive disorder. Download PDFInfo
- Publication number
- ZA200403088B ZA200403088B ZA200403088A ZA200403088A ZA200403088B ZA 200403088 B ZA200403088 B ZA 200403088B ZA 200403088 A ZA200403088 A ZA 200403088A ZA 200403088 A ZA200403088 A ZA 200403088A ZA 200403088 B ZA200403088 B ZA 200403088B
- Authority
- ZA
- South Africa
- Prior art keywords
- treatment
- estra
- propynyl
- depressive disorder
- substance
- Prior art date
Links
- 238000011282 treatment Methods 0.000 title claims description 27
- 208000024714 major depressive disease Diseases 0.000 title claims description 14
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 claims description 48
- 229960000890 hydrocortisone Drugs 0.000 claims description 24
- 239000000203 mixture Substances 0.000 claims description 11
- 238000000034 method Methods 0.000 claims description 9
- 230000001629 suppression Effects 0.000 claims description 8
- DBLOJPKZEOYNBN-SQNIBIBYSA-N (8s,13s,14s)-13-methyl-2,6,7,8,11,12,14,15,16,17-decahydro-1h-cyclopenta[a]phenanthren-3-one Chemical compound C1CC2=CC(=O)CCC2=C2[C@@H]1[C@@H]1CCC[C@@]1(C)CC2 DBLOJPKZEOYNBN-SQNIBIBYSA-N 0.000 claims description 6
- 239000003814 drug Substances 0.000 claims description 6
- 238000002360 preparation method Methods 0.000 claims description 4
- 239000000825 pharmaceutical preparation Substances 0.000 claims description 3
- 230000036470 plasma concentration Effects 0.000 claims description 3
- 239000000126 substance Substances 0.000 claims 8
- 125000002568 propynyl group Chemical group [*]C#CC([H])([H])[H] 0.000 claims 1
- DFELGYQKEOCHOA-BZAFBGKRSA-N (8s,11r,13s,14s,17s)-11-(1,3-benzodioxol-5-yl)-17-hydroxy-13-methyl-17-prop-1-ynyl-1,2,6,7,8,11,12,14,15,16-decahydrocyclopenta[a]phenanthren-3-one Chemical compound C1=C2OCOC2=CC([C@@H]2C3=C4CCC(=O)C=C4CC[C@H]3[C@@H]3CC[C@@]([C@]3(C2)C)(O)C#CC)=C1 DFELGYQKEOCHOA-BZAFBGKRSA-N 0.000 description 23
- 230000001430 anti-depressive effect Effects 0.000 description 11
- 239000002775 capsule Substances 0.000 description 10
- VKHAHZOOUSRJNA-GCNJZUOMSA-N mifepristone Chemical compound C1([C@@H]2C3=C4CCC(=O)C=C4CC[C@H]3[C@@H]3CC[C@@]([C@]3(C2)C)(O)C#CC)=CC=C(N(C)C)C=C1 VKHAHZOOUSRJNA-GCNJZUOMSA-N 0.000 description 10
- AHOUBRCZNHFOSL-YOEHRIQHSA-N (+)-Casbol Chemical compound C1=CC(F)=CC=C1[C@H]1[C@H](COC=2C=C3OCOC3=CC=2)CNCC1 AHOUBRCZNHFOSL-YOEHRIQHSA-N 0.000 description 8
- AHOUBRCZNHFOSL-UHFFFAOYSA-N Paroxetine hydrochloride Natural products C1=CC(F)=CC=C1C1C(COC=2C=C3OCOC3=CC=2)CNCC1 AHOUBRCZNHFOSL-UHFFFAOYSA-N 0.000 description 8
- 230000015572 biosynthetic process Effects 0.000 description 8
- 230000000694 effects Effects 0.000 description 8
- 229960003248 mifepristone Drugs 0.000 description 8
- 229960002296 paroxetine Drugs 0.000 description 8
- 150000003431 steroids Chemical class 0.000 description 8
- 238000003786 synthesis reaction Methods 0.000 description 8
- 239000000935 antidepressant agent Substances 0.000 description 7
- 229940005513 antidepressants Drugs 0.000 description 7
- 239000003862 glucocorticoid Substances 0.000 description 7
- 230000009471 action Effects 0.000 description 6
- 239000003112 inhibitor Substances 0.000 description 6
- 230000000994 depressogenic effect Effects 0.000 description 5
- 101800000414 Corticotropin Proteins 0.000 description 4
- 208000020401 Depressive disease Diseases 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- IDLFZVILOHSSID-OVLDLUHVSA-N corticotropin Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)NC(=O)[C@@H](N)CO)C1=CC=C(O)C=C1 IDLFZVILOHSSID-OVLDLUHVSA-N 0.000 description 4
- 229960000258 corticotropin Drugs 0.000 description 4
- 229960003957 dexamethasone Drugs 0.000 description 4
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 4
- 239000003850 glucocorticoid receptor antagonist Substances 0.000 description 4
- 230000004179 hypothalamic–pituitary–adrenal axis Effects 0.000 description 4
- 239000000275 Adrenocorticotropic Hormone Substances 0.000 description 3
- 102000003676 Glucocorticoid Receptors Human genes 0.000 description 3
- 108090000079 Glucocorticoid Receptors Proteins 0.000 description 3
- 208000028017 Psychotic disease Diseases 0.000 description 3
- 230000003001 depressive effect Effects 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 230000003389 potentiating effect Effects 0.000 description 3
- 208000014311 Cushing syndrome Diseases 0.000 description 2
- 206010054089 Depressive symptom Diseases 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 230000001919 adrenal effect Effects 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 229940126013 glucocorticoid receptor antagonist Drugs 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 239000002395 mineralocorticoid Substances 0.000 description 2
- 239000000902 placebo Substances 0.000 description 2
- 229940068196 placebo Drugs 0.000 description 2
- 201000009395 primary hyperaldosteronism Diseases 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 238000012552 review Methods 0.000 description 2
- 229940037128 systemic glucocorticoids Drugs 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- LDFOACQPUXMYKP-GDSUCZIISA-N (8S,13R,14S)-13-(hydroxymethyl)-17-prop-1-ynyl-2,6,7,8,11,12,14,15,16,17-decahydro-1H-cyclopenta[a]phenanthren-3-one Chemical compound C1CC2=CC(=O)CCC2=C2[C@@H]1[C@@H]1CCC(C#CC)[C@@]1(CO)CC2 LDFOACQPUXMYKP-GDSUCZIISA-N 0.000 description 1
- WNENWYQGQUWBAI-FRVWEUPNSA-N (8S,13S,14S)-7-hydroxy-13-methyl-17-prop-1-ynyl-2,6,7,8,11,12,14,15,16,17-decahydro-1H-cyclopenta[a]phenanthren-3-one Chemical compound OC1[C@H]2[C@@H]3CCC([C@@]3(C)CCC2=C2CCC(C=C2C1)=O)C#CC WNENWYQGQUWBAI-FRVWEUPNSA-N 0.000 description 1
- 206010001367 Adrenal insufficiency Diseases 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 239000000055 Corticotropin-Releasing Hormone Substances 0.000 description 1
- 208000010412 Glaucoma Diseases 0.000 description 1
- 229940127421 Glucocorticoid Synthesis Inhibitors Drugs 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- 206010048675 Pituitary enlargement Diseases 0.000 description 1
- 206010035104 Pituitary tumour Diseases 0.000 description 1
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 210000004100 adrenal gland Anatomy 0.000 description 1
- VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- ROBVIMPUHSLWNV-UHFFFAOYSA-N aminoglutethimide Chemical compound C=1C=C(N)C=CC=1C1(CC)CCC(=O)NC1=O ROBVIMPUHSLWNV-UHFFFAOYSA-N 0.000 description 1
- 229960003437 aminoglutethimide Drugs 0.000 description 1
- 102000001307 androgen receptors Human genes 0.000 description 1
- 108010080146 androgen receptors Proteins 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 230000002800 anti-glucocorticoid effect Effects 0.000 description 1
- 230000001838 anti-progestagenic effect Effects 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 230000001364 causal effect Effects 0.000 description 1
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 1
- 230000010485 coping Effects 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 230000001054 cortical effect Effects 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 230000003292 diminished effect Effects 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 229940011871 estrogen Drugs 0.000 description 1
- 239000000262 estrogen Substances 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 231100000086 high toxicity Toxicity 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- -1 ketoconozole Chemical compound 0.000 description 1
- 230000007257 malfunction Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 229960004465 metyrapone Drugs 0.000 description 1
- FJLBFSROUSIWMA-UHFFFAOYSA-N metyrapone Chemical compound C=1C=CN=CC=1C(C)(C)C(=O)C1=CC=CN=C1 FJLBFSROUSIWMA-UHFFFAOYSA-N 0.000 description 1
- RONZAEMNMFQXRA-UHFFFAOYSA-N mirtazapine Chemical compound C1C2=CC=CN=C2N2CCN(C)CC2C2=CC=CC=C21 RONZAEMNMFQXRA-UHFFFAOYSA-N 0.000 description 1
- 239000004081 narcotic agent Substances 0.000 description 1
- 230000009907 neuroendocrine response Effects 0.000 description 1
- 230000027758 ovulation cycle Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 229940037129 plain mineralocorticoids for systemic use Drugs 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 102000003998 progesterone receptors Human genes 0.000 description 1
- 108090000468 progesterone receptors Proteins 0.000 description 1
- 208000020016 psychiatric disease Diseases 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 239000003488 releasing hormone Substances 0.000 description 1
- 229940023942 remeron Drugs 0.000 description 1
- 230000000580 secretagogue effect Effects 0.000 description 1
- 229940124834 selective serotonin reuptake inhibitor Drugs 0.000 description 1
- 208000019116 sleep disease Diseases 0.000 description 1
- 208000022925 sleep disturbance Diseases 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 210000001541 thymus gland Anatomy 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- 230000002485 urinary effect Effects 0.000 description 1
- 230000004584 weight gain Effects 0.000 description 1
- 235000019786 weight gain Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pain & Pain Management (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP01204072 | 2001-10-26 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA200403088B true ZA200403088B (en) | 2005-01-24 |
Family
ID=8181136
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA200403088A ZA200403088B (en) | 2001-10-26 | 2004-04-22 | Use of (11beta, 17beta)-11-(1,3-benzodioxol-5-yl)-17-hydroxy-17-(1-propynyl)-estra-4,9-dien-3-one in the treatment of major depressive disorder. |
Country Status (26)
| Country | Link |
|---|---|
| US (1) | US20040266863A1 (https=) |
| EP (2) | EP1652526B1 (https=) |
| JP (1) | JP4647909B2 (https=) |
| KR (1) | KR20050038580A (https=) |
| CN (1) | CN100531738C (https=) |
| AT (2) | ATE317700T1 (https=) |
| AU (1) | AU2002348996B2 (https=) |
| BR (1) | BR0213466A (https=) |
| CA (1) | CA2463446C (https=) |
| CY (1) | CY1110173T1 (https=) |
| DE (2) | DE60230936D1 (https=) |
| DK (1) | DK1652526T3 (https=) |
| EC (1) | ECSP045080A (https=) |
| ES (1) | ES2319563T3 (https=) |
| HR (1) | HRP20040370B1 (https=) |
| HU (1) | HUP0500070A3 (https=) |
| IL (2) | IL161248A0 (https=) |
| IS (1) | IS2702B (https=) |
| MX (1) | MXPA04003781A (https=) |
| NO (1) | NO332978B1 (https=) |
| NZ (1) | NZ532429A (https=) |
| PL (1) | PL206687B1 (https=) |
| PT (1) | PT1652526E (https=) |
| RU (1) | RU2302245C2 (https=) |
| WO (1) | WO2003037354A1 (https=) |
| ZA (1) | ZA200403088B (https=) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050080061A1 (en) * | 2003-07-23 | 2005-04-14 | Corcept Therapeutics, Inc. | Antiglucocorticoid therapy for the prevention of neurological damage in premature infants |
| EP2292269A3 (en) * | 2004-11-19 | 2011-08-10 | N.V. Organon | Drug combination comprising a selective serotonin reuptake inhibitor and a glucocorticoid receptor antagonist for the treatment of depression |
| AU2011236053B2 (en) * | 2004-11-19 | 2014-06-26 | Merck Sharpe & Dohme B.V. | Drug combination comprising a selective serotonin reuptake inhibitor and a glucocorticoid receptor antagonist for the treatment of depression |
| JP2009535430A (ja) * | 2006-05-02 | 2009-10-01 | コーセプト セラピューティクス， インコーポレイテッド | Ｉｌ−２を摂取している患者における抑うつを処置するためのグルココルチコイドレセプターｉｉアンタゴニストの使用 |
| EP2671086B1 (en) * | 2011-02-03 | 2018-04-25 | Pop Test Oncology LLC | System and method for diagnosis and treatment |
| US20120263660A1 (en) * | 2011-04-18 | 2012-10-18 | Pop Test Cortisol Llc | Hair Loss Treatment |
| US8986677B2 (en) * | 2012-07-30 | 2015-03-24 | Pop Test Cortisol Llc | Therapeutic compositions and methods |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4814333A (en) * | 1987-07-28 | 1989-03-21 | The Trustees Of Dartmouth College | Method for treatment of hypercortisolemic, depressed patients |
| DE4447401A1 (de) * | 1994-12-23 | 1996-07-04 | Schering Ag | 14,17-C¶2¶-überbrückte Steroide |
| IL118974A (en) * | 1995-08-17 | 2001-09-13 | Akzo Nobel Nv | History 11 - (Transformed Phenyl) - Astra - 4, 9 - Diane, their preparation and pharmaceutical preparations containing them |
| DE19727772A1 (de) * | 1997-06-30 | 1999-01-28 | Forschungszentrum Juelich Gmbh | Magnetflußsensor mit ringförmiger Sonde |
| ATE332696T1 (de) * | 1997-10-06 | 2006-08-15 | Univ Leland Stanford Junior | Methode zur behandlung von durch glycocorticoidstörungen verursachten psychosen |
| CN1820756A (zh) * | 2001-03-23 | 2006-08-23 | 科塞普特治疗公司 | 使用糖皮质激素受体特效拮抗剂治疗压力症的方法 |
| DE60238671D1 (de) * | 2001-05-04 | 2011-02-03 | Corcept Therapeutics Inc | Verwendung von glucocorticoid-rezeptor-spezifischen antagonisten zur behandlung von delirium |
| IL160649A0 (en) * | 2001-08-31 | 2004-07-25 | Corcept Therapeutics Inc | Methods for inhibiting cognitive deterioration in adults with down syndrome |
-
2002
- 2002-10-21 KR KR1020047006050A patent/KR20050038580A/ko not_active Ceased
- 2002-10-21 DE DE60230936T patent/DE60230936D1/de not_active Expired - Lifetime
- 2002-10-21 JP JP2003539697A patent/JP4647909B2/ja not_active Expired - Fee Related
- 2002-10-21 EP EP06101005A patent/EP1652526B1/en not_active Expired - Lifetime
- 2002-10-21 ES ES06101005T patent/ES2319563T3/es not_active Expired - Lifetime
- 2002-10-21 US US10/493,981 patent/US20040266863A1/en not_active Abandoned
- 2002-10-21 BR BR0213466-7A patent/BR0213466A/pt not_active IP Right Cessation
- 2002-10-21 RU RU2004116082/15A patent/RU2302245C2/ru not_active IP Right Cessation
- 2002-10-21 CA CA2463446A patent/CA2463446C/en not_active Expired - Fee Related
- 2002-10-21 NZ NZ532429A patent/NZ532429A/en not_active IP Right Cessation
- 2002-10-21 CN CNB028210417A patent/CN100531738C/zh not_active Expired - Fee Related
- 2002-10-21 PT PT06101005T patent/PT1652526E/pt unknown
- 2002-10-21 DK DK06101005T patent/DK1652526T3/da active
- 2002-10-21 HR HRP20040370AA patent/HRP20040370B1/xx not_active IP Right Cessation
- 2002-10-21 AU AU2002348996A patent/AU2002348996B2/en not_active Ceased
- 2002-10-21 IL IL16124802A patent/IL161248A0/xx unknown
- 2002-10-21 DE DE60209248T patent/DE60209248D1/de not_active Expired - Lifetime
- 2002-10-21 AT AT02781273T patent/ATE317700T1/de active
- 2002-10-21 PL PL369261A patent/PL206687B1/pl not_active IP Right Cessation
- 2002-10-21 WO PCT/EP2002/011732 patent/WO2003037354A1/en not_active Ceased
- 2002-10-21 EP EP02781273A patent/EP1441739B1/en not_active Expired - Lifetime
- 2002-10-21 MX MXPA04003781A patent/MXPA04003781A/es active IP Right Grant
- 2002-10-21 HU HU0500070A patent/HUP0500070A3/hu unknown
- 2002-10-21 AT AT06101005T patent/ATE420649T1/de active
-
2004
- 2004-03-31 IS IS7204A patent/IS2702B/is unknown
- 2004-04-01 IL IL161248A patent/IL161248A/en not_active IP Right Cessation
- 2004-04-22 ZA ZA200403088A patent/ZA200403088B/en unknown
- 2004-04-23 EC EC2004005080A patent/ECSP045080A/es unknown
- 2004-04-23 NO NO20041651A patent/NO332978B1/no not_active IP Right Cessation
-
2009
- 2009-02-02 CY CY20091100116T patent/CY1110173T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| GAILLARD et al. | RU 486 inhibits peripheral effects of glucocorticoids in humans | |
| Nieman et al. | Successful treatment of Cushing’s syndrome with the glucocorticoid antagonist RU 486 | |
| AU624082B2 (en) | Compounds having antiprogestational and anti-estrogenic activities for the treatment of hormone-dependent tumors | |
| TWI477276B (zh) | 抗黃體素給藥方案 | |
| US9616074B2 (en) | Compositions and methods for suppressing endometrial proliferation | |
| US6759399B1 (en) | Use of antimineralocorticoid compounds against narcotic withdrawal syndrome | |
| EP1441739B1 (en) | Use of (11beta, 17beta)-11-(1,3-benzodioxol-5-yl)-17-hydroxy-17-(1-propynyl)-estra-4,9-dien-3-one in the treatment of major depressive disorder | |
| Rapkin et al. | Oral contraceptives and neuroactive steroids | |
| US8193172B2 (en) | Methods for the treatment of major depressive disorder using glucocorticoid receptor antagonists | |
| AU2002348996A1 (en) | Use of (11beta, 17beta)-11-(1,3-benzodioxol-5-yl)-17-hydroxy-17-(1-propynyl)-estra-4,9-dien-3-one in the treatement of major depressive disorder | |
| HK1087357B (en) | Use of (11beta, 17beta)-11-(1,3-benzodioxol-5-yl)-17-hydroxy-17-(1-propynyl)-estra-4,9-dien-3-one in the treatment of major depressive disorder | |
| US20090118253A1 (en) | Compositions and methods for treating dysfunctional uterine bleeding | |
| Dao et al. | Comparative effectiveness of three antiprogestins alone and in combination with anordiol in terminating pregnancy in the rat | |
| LU506495B1 (en) | 17alpha-HYDROXYLASE/17,20-LYASE (CYP17A1) INHIBITORS FOR THE TREATMENT OF SPONTANEOUS HYPERADRENOCORTICISM IN DOGS | |
| Loriaux¹ | Lynnette K. Nieman, 1 George rge P. Chrousos, 1 Charles |